<DOC>
	<DOC>NCT01240096</DOC>
	<brief_summary>Double-blind randomized controlled trials of 8 weeks mirtazapine 15 mg daily or placebo, followed by 8 weeks of open-label mirtazapine 15 mg daily</brief_summary>
	<brief_title>Mirtazapine Versus Placebo in Functional Dyspepsia</brief_title>
	<detailed_description>Double-blind randomized controlled trials of 8 weeks mirtazapine 15 mg or placebo, followed by 8 weeks of open-label mirtazapine Two weeks run-in, 8 weeks randomized, 8 weeks open label Assessments include - dyspepsia questionnaire - Nepean dyspepsia index - Daily diary - Vital signs</detailed_description>
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<criteria>Functional dyspepsia according to Rome II criteria Weight loss of &gt; 5% body weights Organic GI pathology History of upper gi tract surgery Major depression or anxiety Use of antidepressants in the last 2 months Prokinetic drugs or spasmolytic drugs Analgesic use (except paracetamol) Pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Functional dyspepsia</keyword>
	<keyword>Weight loss</keyword>
	<keyword>Mirtazapine</keyword>
</DOC>